Alemtuzumab is a humanised monoclonal antibody targeting the CD52
marker present on B and T lymphocytes, monocytes and macrophages.
Los anticuerpos monoclonales mas usados son aquellos contra el receptor de IL-2 (basiliximab y daclizumab) y el dirigido contra el antigeno CD52
Hale G (2001 ) The CD52
antigen and development of the CAMPATH antibodies.
Jiwon Oh of the division of neurology at the University of Toronto analyzed outcomes of pregnancies among women who had been treated with alemtuzumab (Lemtrada), an antibody that targets CD52
So Qasim and colleagues used a different pair of TALENs to remove a protein called CD52
from the CAR T cells.
sup], Alemtuzumab is a humanized mAb targeting the cell surface antigen CD52
, which is expressed on more than 95% of all normal B lymphocytes, T lymphocytes, and monocytes.
Its antibody action is directed against cell surface glycoprotein CD52
Antibodies include but are not limited to HER2/neu (Epidermal Growth Factor Receptor), ER (Estrogen Receptor alpha & beta), PR (Progesterone Receptor), CD20, CD30, and CD52
According to the company, Alemtuzumab is a monoclonal antibody that selectively targets CD52
, a protein abundant on T and B cells.
In addition to CD56, plasmacytomas may aberrantly express CD117, CD20, CD52
, CD10, and EMA.
It acts by targeting the surface antigen CD52
expressed on lymphocytes and monocytes resulting in lymphopaenia.
Alemtuzumab is a humanised IgG1 mAb that binds to CD52
on leucocytes, including T- and B-cells, natural killer cells, monocytes and macrophages, depleting these cells.